272 results on '"Bot, Adrian"'
Search Results
2. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma
3. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
4. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
5. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
6. Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.
7. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
8. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
9. Liquid biopsy approach to monitor the efficacy and response to CAR-T cell therapy
10. KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results
11. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma
12. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
13. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
14. Multidimensional single-cell analysis identifies a role for CD2-CD58 interactions in clinical antitumor T cell responses
15. Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
16. IL7 increases targeted lipid nanoparticle-mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation.
17. Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL
18. A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies
19. New section in journal of translational medicine: patient-targeted molecular therapies
20. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)
21. Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies
22. Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma
23. Abstract CT004: Product attributes of axicabtagene ciloleucel (axi-cel) that associate differentially with efficacy and toxicity in second-line large B-cell lymphoma
24. Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL)
25. Safety and Preliminary Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Axicabtagene Ciloleucel in Combination with Utomilumab in Adults with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-11, NCT03704298)
26. Antigen Kinetics Determines Immune Reactivity
27. Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T
28. Effects of Prior Exposure to Tec Kinase(BTK/ITK) Inhibitors on Kte-X19 Products
29. A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
30. Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms
31. Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)
32. TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma
33. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
34. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
35. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
36. CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel
37. Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel)
38. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
39. Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
40. 90 Potentiation of T-cell mediated tumor killing via modulation of the fas/fasL pathway
41. Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy
42. CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel
43. Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination
44. JTM’s Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section
45. 207 - Pre and Post-Treatment CD27+ T Cells Track with Clinical Efficacy of Axi-Cel in DLBCL Patients
46. 76 - Safety and Preliminary Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Axicabtagene Ciloleucel in Combination with Utomilumab in Adults with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-11, NCT03704298)
47. 10 - Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL)
48. Abstract CT153: Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1
49. Abstract 1204: Design and development of anti-linker antibodies for the detection and characterization of CAR T cells
50. 2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.